ATE422215T1 - Strategie zur unterdruckung der expression eines endogenen genes durch verwendung von verbindungen,die an die nicht-kodierenden regionen des zu hemmenden genes binden können - Google Patents
Strategie zur unterdruckung der expression eines endogenen genes durch verwendung von verbindungen,die an die nicht-kodierenden regionen des zu hemmenden genes binden könnenInfo
- Publication number
- ATE422215T1 ATE422215T1 AT96931887T AT96931887T ATE422215T1 AT E422215 T1 ATE422215 T1 AT E422215T1 AT 96931887 T AT96931887 T AT 96931887T AT 96931887 T AT96931887 T AT 96931887T AT E422215 T1 ATE422215 T1 AT E422215T1
- Authority
- AT
- Austria
- Prior art keywords
- gene
- strategy
- coding regions
- expression
- bind
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title 1
- 108091026890 Coding region Proteins 0.000 abstract 2
- 239000012636 effector Substances 0.000 abstract 2
- 230000001629 suppression Effects 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9519299.3A GB9519299D0 (en) | 1995-09-21 | 1995-09-21 | Genetic strategy |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE422215T1 true ATE422215T1 (de) | 2009-02-15 |
Family
ID=10781063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96931887T ATE422215T1 (de) | 1995-09-21 | 1996-09-23 | Strategie zur unterdruckung der expression eines endogenen genes durch verwendung von verbindungen,die an die nicht-kodierenden regionen des zu hemmenden genes binden können |
Country Status (10)
Country | Link |
---|---|
US (2) | US6713457B2 (de) |
EP (1) | EP0851918B1 (de) |
AT (1) | ATE422215T1 (de) |
AU (1) | AU7089696A (de) |
CA (1) | CA2232738C (de) |
DE (1) | DE69637831D1 (de) |
ES (1) | ES2321461T3 (de) |
GB (1) | GB9519299D0 (de) |
NZ (1) | NZ318818A (de) |
WO (1) | WO1997011169A2 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9519299D0 (en) | 1995-09-21 | 1995-11-22 | Farrar Gwyneth J | Genetic strategy |
GB9604449D0 (en) * | 1996-03-01 | 1996-05-01 | Farrar Gwyneth J | Genetic strategy ii |
GB9606961D0 (en) | 1996-04-02 | 1996-06-05 | Farrar Gwyneth J | Genetic strategy III |
US20040234999A1 (en) * | 1996-04-02 | 2004-11-25 | Farrar Gwenyth Jane | Genetic suppression and replacement |
US8551970B2 (en) * | 1996-04-02 | 2013-10-08 | Optigen Patents Limited | Genetic suppression and replacement |
WO1998048027A2 (en) * | 1997-04-21 | 1998-10-29 | University Of Florida | Materials and methods for treatment of retinal diseases |
CA2287508A1 (en) | 1997-04-21 | 1998-10-29 | The University Of Florida | Materials and methods for ribozyme treatment of retinal diseases |
US20040138168A1 (en) * | 1999-04-21 | 2004-07-15 | Wyeth | Methods and compositions for inhibiting the function of polynucleotide sequences |
AU781598B2 (en) * | 1999-04-21 | 2005-06-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibiting the function of polynucleotide sequences |
WO2000066780A2 (en) | 1999-04-30 | 2000-11-09 | University Of Florida | Adeno-associated virus-delivered ribozyme compositions and methods of use |
GB0403600D0 (en) * | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
EP1764107A1 (de) * | 2005-09-14 | 2007-03-21 | Gunther Hartmann | Zusammensetzungen enthaltend immunstimulierende RNA-Oligonukleotide und Methoden zu deren Herstellung |
US8557787B2 (en) | 2011-05-13 | 2013-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
JPH0376580A (ja) | 1989-08-17 | 1991-04-02 | Japan Tobacco Inc | 大腸菌発現ベクターとそれを利用した抗ウイルス性タンパク質の製造方法 |
US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5223391A (en) * | 1990-02-21 | 1993-06-29 | President And Fellows Of Harvard College | Inhibitors of herpes simplex virus replication |
US5246921A (en) * | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
NO312681B1 (no) | 1990-08-24 | 2002-06-17 | Univ California | Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet |
CA2094938A1 (en) | 1991-01-04 | 1992-07-05 | Grant R. Sutherland | Dna sequences related to isolated fragile x syndrome |
DK51092D0 (da) * | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
CA2111472A1 (en) * | 1991-06-14 | 1992-12-23 | Brett P. Monia | Antisense oligonucleotide inhibition of the ras gene |
AU3274793A (en) | 1991-12-12 | 1993-07-19 | Hybritech Incorporated | Enzymatic inverse polymerase chain reaction library mutagenesis |
IL101600A (en) * | 1992-04-15 | 2000-02-29 | Yissum Res Dev Co | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
US6107062A (en) | 1992-07-30 | 2000-08-22 | Inpax, Inc. | Antisense viruses and antisense-ribozyme viruses |
WO1994011494A1 (en) * | 1992-11-09 | 1994-05-26 | Thomas Jefferson University | Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen |
CA2159195A1 (en) * | 1993-03-26 | 1994-10-13 | Darwin J. Prockop | Use of a col 1a1 mini-gene construct to inhibit collagen synthesis |
CN1123038A (zh) | 1993-05-11 | 1996-05-22 | 北卡罗来纳大学查珀尔希尔分校 | 阻止异常剪接的反义寡核苷酸及其使用方法 |
US6025127A (en) * | 1994-01-14 | 2000-02-15 | The Johns Hopkins University School Of Medicine | Nucleic acid mutation detection in histologic tissue |
US5834440A (en) * | 1994-03-07 | 1998-11-10 | Immusol Incorporated | Ribozyme therapy for the inhibition of restenosis |
WO1995034573A1 (en) | 1994-06-03 | 1995-12-21 | Brigham And Women's Hospital | Identification of polycystic kidney disease gene, diagnostics and treatment |
US5807718A (en) * | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
US6482803B1 (en) * | 1995-09-01 | 2002-11-19 | Board Of Regents, The University Of Texas System | Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A |
GB9519299D0 (en) | 1995-09-21 | 1995-11-22 | Farrar Gwyneth J | Genetic strategy |
WO1997044348A1 (en) * | 1996-05-17 | 1997-11-27 | Thomas Jefferson University | Ribozyme-mediated gene replacement |
US5814500A (en) | 1996-10-31 | 1998-09-29 | The Johns Hopkins University School Of Medicine | Delivery construct for antisense nucleic acids and methods of use |
-
1995
- 1995-09-21 GB GBGB9519299.3A patent/GB9519299D0/en active Pending
-
1996
- 1996-09-23 ES ES96931887T patent/ES2321461T3/es not_active Expired - Lifetime
- 1996-09-23 US US09/043,506 patent/US6713457B2/en not_active Expired - Lifetime
- 1996-09-23 AT AT96931887T patent/ATE422215T1/de not_active IP Right Cessation
- 1996-09-23 DE DE69637831T patent/DE69637831D1/de not_active Expired - Lifetime
- 1996-09-23 WO PCT/GB1996/002357 patent/WO1997011169A2/en active Application Filing
- 1996-09-23 CA CA2232738A patent/CA2232738C/en not_active Expired - Fee Related
- 1996-09-23 EP EP96931887A patent/EP0851918B1/de not_active Expired - Lifetime
- 1996-09-23 AU AU70896/96A patent/AU7089696A/en not_active Abandoned
- 1996-09-23 NZ NZ318818A patent/NZ318818A/en not_active IP Right Cessation
-
2003
- 2003-12-19 US US10/742,656 patent/US20040254138A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GB9519299D0 (en) | 1995-11-22 |
AU7089696A (en) | 1997-04-09 |
WO1997011169A2 (en) | 1997-03-27 |
EP0851918A2 (de) | 1998-07-08 |
US6713457B2 (en) | 2004-03-30 |
US20030096767A1 (en) | 2003-05-22 |
CA2232738A1 (en) | 1997-03-27 |
ES2321461T3 (es) | 2009-06-05 |
EP0851918B1 (de) | 2009-02-04 |
US20040254138A1 (en) | 2004-12-16 |
NZ318818A (en) | 2000-06-23 |
WO1997011169A3 (en) | 1997-06-12 |
DE69637831D1 (de) | 2009-03-19 |
CA2232738C (en) | 2010-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE422215T1 (de) | Strategie zur unterdruckung der expression eines endogenen genes durch verwendung von verbindungen,die an die nicht-kodierenden regionen des zu hemmenden genes binden können | |
EP1092771A3 (de) | Tetracyclin-regulierte Transcriptionsmodulatoren | |
ATE513911T1 (de) | Verfahren und zusammensetzungen für rna- interferenz | |
ATE206465T1 (de) | Verfahren zur unterdrückung der hemmung von enzym-vermittelten reaktionen durch ionische detergentien | |
AU2022295A (en) | Nucleic acid amplification with DNA-dependant RNA polymerase activity of RNA replicases | |
DE60030988D1 (de) | Verfahren zur Herstellung Von L-Aminosäuren durch Erhöhung des zellulären NADPH | |
DK0966465T3 (da) | Inhibitorer af IMPDH-enzymer | |
DE69638061D1 (de) | Onkogenische mutanten des genes tsg101 | |
GB2325302B (en) | Cross-species chromosome painting | |
ATE166066T1 (de) | Schutz von nukleinsäuren und verfahren zur analyse | |
DE59909391D1 (de) | Verfahren zur Herstellung von Pantothensäure durch Verstärkung von für Ketopantoat-Reduktase kodierende Nukleotidsequenzen | |
AU7517496A (en) | Methods for preparing solid supports for hybridization and reducing non-specific background | |
DE69810351D1 (de) | Verfahren zur begrenzung des wachstums von mikroorganismen durch verwendung metallhaltiger verbindungen | |
ATE250077T1 (de) | Steroid sulfataseinhibitoren, verfahren zu ihrer herstellung und verwendung | |
ATE399749T1 (de) | Verfahren zur hydrierung von methylolalkanalen | |
HUP9802681A1 (hu) | Onkogénnel vagy vírussal szabályozott expressziós rendszerek | |
Rovera et al. | Ghost monolayers in the study of the modulation of transcription in cultures of CV1 fibroblasts | |
DE69941451D1 (de) | Verfahren zur unterdrückung der genexpression in pflanzen | |
GB2397825A (en) | Method of producing human beta cell lines | |
HUP0100126A2 (hu) | Előaktivált kiméra transzkripciós faktorok | |
SG125896A1 (en) | A method for regulating gene expression | |
O’Neill et al. | The role of ncRNA in centromeres: a lesson from marsupials | |
DE60130465D1 (de) | Mutierte muskelspezifische enhancer | |
DE50105621D1 (de) | 1h-pyrazol-derivate, verfahren zu ihrer herstellung und deren verwendung zur hemmung und steuerung der nitrifikation | |
DE69924718D1 (de) | Gen 62 des attenuierten windpocken-virusstammes oka und verfahren zur identifikation eines attenuierten, lebenden windpockenvirusstammes unter verwendung dieses genes. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |